Reprogramming Metabolism
to Reverse the Cancer Cascade
Clinical-stage biopharmaceutical company advancing
oncology and onco-dermatology therapies.
Science & Clinical
Pioneering metabolic reprogramming for dermatology and oncology.
Explore Our Science → Investor Relations
Stay updated on our latest financial and corporate developments.
Investor Relations →Key Milestones
- Phase 2B* EMA Research Study Ongoing in Advanced Actinic Keratosis (Germany)
- Phase 2B FDA Study Completed in Actinic Keratosis
- Shares Publicly Traded on Xetra & Tradegate (T9G)
- Seven Global Patent Families Secured